Stock MMQ MIND MEDICINE (MINDMED) INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Mind Medicine (MindMed) Inc. Deutsche Boerse AG

Equities

MMQ

CA60255C8850

Real-time Estimate Tradegate
Other stock markets
 06:38:24 2024-07-18 EDT 		5-day change 1st Jan Change
7.643 EUR -0.61% Intraday chart for Mind Medicine (MindMed) Inc. +16.92% +123.55%
07-17 Mind Medicine Says New Patent Secured for Investigational Anxiety Disorder Treatment MM120 MT
07-17 Mind Medicine Inc. Announces Issuance of New Patent for MM120 Orally Disintegrating Tablet CI

Evolution of the average Target Price on Mind Medicine (MindMed) Inc.

Price target over the last 5 years

History of analyst recommendation changes

ff00321715041.zCDtR-YqZ-YIZ_5yUO5QaWoBbFYuSvqMUjrzk7Q5uo0.h0zeBNBEE5JGEo1KAZoIKiU5Wz1LPIDaB1mR6o1f-eu9SZox1kQjvEUBvw~f971775495fa3b780c2e3fffa1c68adc

Analyst Recommendations on Mind Medicine (MindMed) Inc.

Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug MT
Baird Starts Mind Medicine (MindMed) With Outperform Rating, $27 Price Target MT
Oppenheimer Adjusts Mind Medicine Price Target to $20 From $29, Maintains Outperform Rating MT
Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target MT
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk MT
Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating MT
RBC Lifts Price Target on Mind Medicine (MindMed) to $15 From $14, Notes Imminent Durability Data; Outperform, Speculative Risk Kept MT
RBC Raises Price Target on Mind Medicine (MindMed) to $7 From $5, Maintains Outperform, Speculative Risk MT
EF Hutton Initiates Mind Medicine at Buy With $21 Price Target MT
Mind Medicine (MindMed) Initiated at Outperform by RBC With $5 Price Target, Speculative Risk Qualifier; Firm Sees 'Opportunity for Upside' MT
HC Wainwright Adjusts Mind Medicine's Price Target to $75 from $5, Retains Buy Rating MT
Oppenheimer Initiates Coverage on Mind Medicine With Outperform Rating, $3.50 Price Target MT
HC Wainwright Adjusts Mind Medicine's Price Target to $5 From $10, Maintains Buy Rating MT
Cantor Fitzgerald Starts Mind Medicine at Overweight With $3 Price Target MT
Roth Capital Starts MindMed at Buy With $7 Price Target MT
MIND MEDICINE MINDMED : HC Wainwright Starts MindMed at Buy With $10 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
8.39 USD
Average target price
24.25 USD
Spread / Average Target
+189.03%
High Price Target
36 USD
Spread / Highest target
+329.08%
Low Price Target
16 USD
Spread / Lowest Target
+90.70%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Mind Medicine (MindMed) Inc.

Baird
Oppenheimer
Leerink Partners
RBC Capital Markets
Roth MKM
EF Hutton
HC Wainwright
Cantor Fitzgerald
Roth Capital Partners

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. MNMD Stock
  4. MMQ Stock
  5. Consensus Mind Medicine (MindMed) Inc.